Earnings Summary

Silverback Therapeutics Inc’s net profit jumped 21.15% since last year same period to $-17.86Mn in the Q3 2022. On a quarterly growth basis, Silverback Therapeutics Inc has generated 8.05% jump in its net profits since last 3-months.

Silverback Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a 5.41% jump from last quarter’s estimates.

Silverback Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.35.

Silverback Therapeutics Inc’s earning per share (EPS) jumped 21.43% since last year same period to -0.55 in the Q2 2022. This indicates that the Silverback Therapeutics Inc has generated 21.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Silverback Therapeutics Inc’s return on assets (ROA) stands at -0.17.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Silverback Therapeutics Inc’s return on equity (ROE) stands at -0.28.